Mirapex Class Action Library
The below links will take you to various press releases and notices dealing with the Mirapex Class Action.
For your convenience and to avoid software compatibility issues, they have been formatted in PDF. Therefore, to view and/or print these items, you will need Adobe Acrobat Reader. If you do not have Acrobat Reader, you may download this free program from Adobe by clicking here.
Mirapex Update: Certification Motion
Posted: March 3, 2011
On March 1st and 2nd, 2011, the Honourable Mr. Justice Strathy of the Ontario Superior Court of Justice heard the plaintiff’s Motion for Certification in the Mirapex class action. The Court has reserved his decision, meaning that it may take several weeks before his decision is released. The decision will be posted under the Mirapex section of our website as soon as it is released.
Mirapex Class Action Update: Recent U.S. Court Punitive Damages Order
Posted: November 2007
On November 26, 2007, a U.S. Court allowed various Mirapex claimants to claim punitive damages against the drug manufacturers of the dopamine agonist drug Mirapex. Click here to review a copy of the U.S. Court decisions. At pages 10 through 18 of the decision, the US Court summarizes in great detail the facts relied on by the Mirapex claimants.
Houston Press Article (Mirapex)
Posted: September 2005
Overstimulated – How taking a Parkinson’s disease wonder drug apparently makes some people want to gamble and have sex all the time.
Gambling Addiction Leads To National Class Action Lawsuit (Mirapex)
Posted: May 2005
A national Class Action lawsuit has been launched claiming that people with Parkinson’s disease developed a gambling addiction as a result of their use of the drug Mirapex. The plaintiffs, who are represented by the Toronto law firm of Thomson Rogers, seek millions of dollars in compensation from the drug’s Canadian manufacturer, Boehringer Ingelheim (Canada) Ltd., and two American corporations.
Mirapex Class Action Statement of Claim
Posted: May 2005
Statement of Claim between Gerard Schick and Boehringer Ingelheim (Canada) Ltd., Boehringer Ingelheim Pharmaceuticals Inc. and Pfizer Inc.